{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:48:51Z","timestamp":1788306531419,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["NZ7\/04315"],"award-info":[{"award-number":["NZ7\/04315"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.vaccine.2015.11.070","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T02:06:18Z","timestamp":1450317978000},"page":"510-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland"],"prefix":"10.1016","volume":"34","author":[{"given":"Izabela","family":"Wa\u015bko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"De Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Moschioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Skoczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.11.070_bib0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1574-6976.2006.00051.x","article-title":"Conquering the meningococcus","volume":"31","author":"Stephens","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erv.10.3","article-title":"The epidemiology of meningococcal disease and the impact of vaccines","volume":"9","author":"Khatami","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0180","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/14656566.5.4.855","article-title":"Meningococcal conjugate vaccines","volume":"5","author":"Zimmer","year":"2004","journal-title":"Expert Opin Pharmacother"},{"issue":"6516","key":"10.1016\/j.vaccine.2015.11.070_bib0185","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/373715a0","article-title":"Molecular characterization of eukaryotic polysialyltransferase-1","volume":"373","author":"Eckhardt","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0190","doi-asserted-by":"crossref","first-page":"15349","DOI":"10.1074\/jbc.M208837200","article-title":"Functional relationships of the sialyltransferases involved in expression of the polysialic acid capsules of Escherichia coli K1 and K92 and Neisseria meningitidis groups B or C","volume":"278","author":"Steenbergen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0195","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.11.070_bib0200","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.1016\/j.vaccine.2011.12.060","article-title":"History of meningococcal vaccines and their serological correlates of protection","volume":"30","author":"Vipond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0205","unstructured":"Food and Drug Administration. First vaccine approved by FDA to prevent serogroup B Meningococcal disease. Available from \u3008http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm420998.htm.\u3009; 2015 [accessed June 2015]."},{"key":"10.1016\/j.vaccine.2015.11.070_bib0210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0215","unstructured":"European Medicines Agency. European Medicines Agency recommends approval of first vaccine for meningitis B, 16 November 2012, EMA\/CHMP\/728052\/2012; Available from \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2012\/11\/WC500134846.pdf.\u3009; 2015 [accessed June 2015]."},{"key":"10.1016\/j.vaccine.2015.11.070_bib0220","unstructured":"Summary Basis of Decision (SBD): Bexsero\u00ae\u2014Health Canada. Available from \u3008http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2014_bexsero_147275-eng.php.\u3009; 2014 [accessed June 2014]."},{"key":"10.1016\/j.vaccine.2015.11.070_bib0225","unstructured":"Diario Oficial da Uniao Republica Federativa do Brasil\u2013Imprensa Nacional. Bras\u00edlia\u2013DF, segunda-feira, 5.01.2015 (suppl. 2). Available from \u3008http:\/\/sites.unasp.edu.br\/portal\/secretariageral\/Documentos\/DOU\/2015-1\/01\/DO1_2015_01_05_SuplementoAnvisa.pdf.\u3009; 2015 [accessed August 2015]."},{"key":"10.1016\/j.vaccine.2015.11.070_bib0230","unstructured":"Food and Drug Administration. FDA approves a second vaccine to prevent serogroup B meningococcal disease. Available from \u3008http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm431370.htm.\u3009; 2015 [accessed June 2015]."},{"key":"10.1016\/j.vaccine.2015.11.070_bib0235","unstructured":"Australian Public Assessment Report for Multi-Component Meningococcal B vaccine. Available from \u3008https:\/\/www.tga.gov.au\/auspar\/auspar-multi-component-meningococcal-b-vaccine.\u3009 [accessed June 2015]."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.11.070_bib0240","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0245","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0250","article-title":"Commission decision of 22 December 1999 on the communicable diseases to be progressively covered by the community network under decision number 2119\/98\/EC of the Parliament and of the Council","year":"2015","journal-title":"Off J Eur Commun L28\/50"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0255","article-title":"Decision number 2119\/98\/EC of the European Parliament and of the Council of 24 September 1998: setting up a network for the epidemiological surveillance and control of communicable diseases in the community","year":"2015","journal-title":"Off J Eur Commun L268\/1"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0260","doi-asserted-by":"crossref","first-page":"e71943","DOI":"10.1371\/journal.pone.0071943","article-title":"A decade of invasive meningococcal disease surveillance in Poland","volume":"8","author":"Skoczy\u0144ska","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0265","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS: a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0270","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0275","unstructured":"Jolley KA, Maiden MC. In: Oxford Uo, editor. Neisseria Multi Locus Sequence Typing website. Wellcome Trust and European Union; 2012-09-26."},{"key":"10.1016\/j.vaccine.2015.11.070_bib0280","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0285","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","article-title":"Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus","volume":"27","author":"Bambini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0290","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/CVI.00133-14","article-title":"Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development","volume":"21","author":"Brehony","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0295","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of meningococcal multicomponent vaccine in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0300","first-page":"103","article-title":"Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic","volume":"63","author":"K\u0159\u00ed\u017eov\u00e1","year":"2014","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2180-14-111","article-title":"Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine","volume":"14","author":"Tzanakaki","year":"2014","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0315","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/JB.06161-11","article-title":"In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva","volume":"194","author":"Fagnocchi","year":"2012","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0320","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/IAI.01085-12","article-title":"Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts on the prediction of coverage of the 4CMenB vaccine","volume":"81","author":"Fagnocchi","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0325","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.070_bib0330","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/CVI.00669-14","article-title":"A large portion of meningococcal antigen typing system-negative meningococcal strains from Spain is killed by sera from adolescents and infants immunized with 4CMenB","volume":"22","author":"Abad","year":"2015","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15017648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15017648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T05:30:00Z","timestamp":1692163800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15017648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0264410X15017648"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}